Zejing Pharmaceuticals: Approval of clinical trials for the treatment of lung cancer with injection ZG006 combination therapy.

Zejing Pharmaceuticals announced that the company recently received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration for the clinical trial approval of the injection of ZG006 in combination with the injection of HS-20093, with or without the injection of Atezolizumab, for the treatment of extensive-stage small cell lung cancer. ZG006 is a triple-specific antibody drug, while HS-20093 is a novel B7-H3-targeted ADC. The approval of this clinical trial will not have a significant impact on the company's recent performance. Drug research and development is subject to uncertainties, and there is a risk that the drug may not be approved for sale.